Olema Oncology to Present New Palazestrant and Ribociclib Data at 2024 ESMO Breast Cancer Congress

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a biopharmaceutical company dedicated to the advancement of targeted therapies for women's cancers, has announced the presentation of new data from its ongoing Phase 1b/2 clinical trial. The study investigates the combination of palazestrant (OP-1250) and the CDK4/6 inhibitor ribociclib in patients with advanced and/or metastatic breast cancer. This presentation will take place at the European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress 2024 from May 15-17 in Berlin, Germany.

The specific details of the scheduled poster presentation at the ESMO Congress are as follows:
- Title: A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-), advanced and/or metastatic breast cancer (ID 407)
- Presentation Number: 212P
- Date: Thursday, May 16, 2024
- Time: 12:00 p.m. CEST (6:00 a.m. ET)

The poster will be accessible on Olema’s website under the Science section once it is presented at the congress. Abstracts can be found on the ESMO Breast Cancer Annual Congress website.

In conjunction with the ESMO presentation, Olema will host a webcast and conference call for analysts and investors on May 15, 2024, at 8:00 a.m. ET to discuss the data. Registration for the webcast can be done through the Investors & Media section of Olema's website.

Palazestrant (OP-1250) is an oral small molecule that functions as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is being tested in patients with recurrent, locally advanced, or metastatic ER-positive (ER+), HER2-negative breast cancer. Studies have shown that palazestrant can fully inhibit ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer. The drug has exhibited anti-tumor efficacy, favorable pharmacokinetics, tolerability, CNS penetration, and compatibility with CDK4/6 inhibitors.

Palazestrant has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of ER+/HER2- metastatic breast cancer that has advanced following one or more lines of endocrine therapy, including at least one line combined with a CDK4/6 inhibitor. It is currently being evaluated as a monotherapy in a Phase 3 clinical trial (OPERA-01), and in Phase 1/2 combination studies with various inhibitors including CDK4/6 (palbociclib and ribociclib), PI3Ka (alpelisib), and mTOR (everolimus).

Olema Oncology, based in San Francisco with operations in Cambridge, Massachusetts, is committed to transforming cancer care and enhancing outcomes for women with cancer. The company is developing a pipeline of innovative therapies, drawing on its deep expertise in endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Besides its leading candidate palazestrant, Olema is also developing a potent KAT6 inhibitor (OP-3136).